Omani experience with the use of factor IX Fc fusion protein

Shireen I. Alzadjali*, Yasser Wali

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.

Original languageEnglish
Article numbere241154
JournalBMJ Case Reports
Issue number7
Publication statusPublished - Jul 21 2021
Externally publishedYes


  • congenital disorders
  • haematology (incl blood transfusion)
  • paediatrics

ASJC Scopus subject areas

  • Medicine(all)

Cite this